Juvenile Idiopathic Arthritis
Conditions
Keywords
juvenile, arthritis, diet
Brief summary
The aim of this study is to explore if an already established diet with anti-inflammatory effect in paediatric inflammatory bowel disease would have an anti-inflammatory effect in children with JIA. The diet is called specific carbohydrate diet.
Detailed description
Children classified with JIA, in a low-to-medium disease activity and without having changed DMARD or bDMARD in the last 12 weeks are included. Only motivated children and parents can participate. Before inclusion the family are informed orally about the study plan, the diet and practical issues regarding the study and they receive written information including for example a product list and a recipe booklet. A dietician and the principal investigator follows the child and parents during visits, by mail and phone. After the baseline visit, the family has two weeks to get used to the new diet. At baseline, after two, four and twelve weeks on the diet the child is examined, blood exams are performed and blood is stored at -70, fecal samples and urine is also collected. At inclusion and after four weeks saliva sample for bacteria is collected. The child fills in the child health assessment questionnaire, (CHAQ) for a score of the physical ability and DisabKids for an overall assessment of the childs well-being.
Interventions
Specific carbohydrate diet (see arm description)
Sponsors
Uppsala University
Swedish University of Agricultural Sciences
Chalmers University of Technology
The Swedish Rheumatism Ass
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Except for outcome in clinical variables, JADAS27, CHAQ, Morning stiffness and pain from one month of SCD we are now analyzing possible change in metabolites in plasma samples and possible metagenomic shift in fecal samples.
Eligibility
Sex/Gender
ALL
Age
No minimum to 16 Years
Healthy volunteers
No
Inclusion criteria
* Participants should fulfill criteria for JIA according to the ILAR criteria * Participants should not be older than 16 years at onset of disease * Participants should have a low-medium disease activity with an E-SR of 30 at the most and/or no more than two active joints at inclusion. * DMARD and bDMARD should not have been changed within the last 12 weeks before inclusion. * Any gastro- intestinal complaints should be investigated before inclusion. * Fecal calprotectin should be normal. * The child as well as the parents need to be motivated for the child to try a dietary intervention for at least four weeks, preferably longer.
Exclusion criteria
* Children with the systemic category of JIA. * Children with an unstable inflammatory situation with \> 2 inflamed joints and/or an E-SR of more than 30.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in overall well-being | At baseline compared to four weeks of intervention | Global assessment visual analogue scale (VAS), for the patient min-max, 0-10 cm. A higher score means worse overall well-being |
| Change in number of inflamed joints | At baseline compared to four weeks of intervention | Physical examination |
| Change in CHAQ, child health assessment questionnaire | At baseline compared to four weeks of intervention | A questionnaire for assessment of physical function, min-max, 0-3. A higher score means worse physical function |
| Change in assessment of pain: visual analogue scale | At baseline compared to four weeks of intervention | Global assessment visual analogue scale (VAS) for Pain, min-max, 0-10 cm. A higher score means more pain |
| Change in assessment of morning stiffness | At baseline compared to four weeks of intervention | Number of minutes |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Short chain fatty acids in fecal samples | At baseline compared to four weeks of intervention | Analysed, using a HPLC-machine, Agilent technology 1100-series, presented in mg/gr |
| Change in Microbiota in fecal samples | At baseline compared to four weeks of intervention | 16sSrRNA and Metagenomics |
Countries
Sweden
Outcome results
None listed